Document:

Exhibit 4.9

 

SECOND
CONVERTIBLE REVOLVING DEMAND PROMISSORY 2019 NOTE

 

Inhibikase Therapeutics, Inc.

Atlanta, Georgia

 

THIS SECOND CONVERTIBLE REVOLVING DEMAND
PROMISSORY 2019 NOTE (THE “2019 Note”) AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT AND WILL NOT HAVE
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), APPLICABLE STATE SECURITIES LAWS
OR APPLICABLE LAWS OF ANY FOREIGN JURISDICTION. THIS 2019 Note HAS BEEN AND SUCH UNDERLYING SECURITIES HAVE BEEN, AS THE CASE MAY
BE, ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED,
RENOUNCED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF EITHER (A) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND
ANY APPLICABLE STATE SECURITIES LAWS OR, IF APPLICABLE, ANY FOREIGN JURISDICTION OR (B) IN THE OPINION OF COUNSEL SATISFACTORY
TO COMPANY, THE AVAILABILITY OF AN EXEMPTION FROM THE REGISTRATION PROVISIONS OF THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE
STATE SECURITIES LAWS OR, IF APPLICABLE, ANY FOREIGN JURISDICTION.

 

Except as otherwise defined in the
text hereof, capitalized terms and phrases shall have the meaning ascribed thereto in Section 7 of this 2019 Note.

 

	$575,375	Issue Date: December 31,
2019

 

 

Inhibikase Therapeutics,
Inc. (hereinafter “Maker”) promises to pay to Joseph Frattaroli (hereinafter “Payee”) the amount of Two
Hundred Seventy-Five Thousand Three Hundred Seventy-Five dollars ($275,375) plus an additional sum of up to Three Hundred Thousand
Dollars ($300,000) or such amount as is accrued from time to time by Maker in unpaid fees, accrued interest and costs incurred
for and on its behalf (the “Fees and Costs”) as are from time to time reflected on Payee’s monthly statements
for services rendered (the “Statements”), whichever amount is less (the “Principal”), together with
interest thereon from and after the date hereof until paid in full, all as provided in this Second Convertible Revolving Demand
Promissory 2019 Note. The Maker and the Payee acknowledge and agree that the 2019 Note is entered into, in part, as full consideration
for that certain Convertible Revolving Demand Promissory Note dated April 3, 2018 (the “2018 Note”) by and between
Joseph Frattaroli and Inhibikase Therapeutics, Inc. plus any amounts above and beyond the face amount of the 2018 Note due by Inhibikase
Therapeutics, Inc. to Joseph Frattaroli from the beginning of time up to and including December 31, 2019. Maker and Payee agree
that the balance due under the 2019 Note for Fees and Costs shall be updated based on Payee’s Statements as the same are
published from time to time by modifying that certain schedule entitled “Schedule of Fees and Costs,” which is attached
hereto, marked as Exhibit “A,” and made a part hereof, to reflect such updated balance; provided, however,
that such updating shall only serve as a ministerial act in accounting for the Principal amount, and any failure to perform or
delay in performing such updating shall in no event affect the amount due under the 2019 Note.

 

    

     

    

 

1.            
 Payment of Principal and Interest.

 

(a)              
Payment in Cash. This2019 Note is payable either in full or in part until paid in full, as the case may be, without
demand and in immediately available funds, not later than the earlier to occur of either a Significant Transaction or the 31st
day of December, 2021 (either such date, the “Maturity Date”).

 

(b)              
Interest. From and including the Issue Date to and including the date this 2019 Note is paid or otherwise discharged
in full, the unpaid Principal amount of this 2019 Note shall bear simple interest at Five Percent (5%) per annum, computed on the
basis of a year of 360 days; provided, however, that upon the occurrence, and during the continuance of an Event
of Default hereunder, this 2019 Note shall bear simple interest at Twelve Percent (12%) per annum, computed on the basis of a year
of 360 days.

 

(c)              
Tender. All payments of Principal and interest shall be made in lawful money of the United States of America and
shall be made to Payee via wire transfer or certified check to an account designated by Payee or, if no account is so designated,
at Payee’s address or at such other place as Payee may designate to Maker in writing in accordance with Section 13 of this
2019 Note.

 

2.            
Obligation to Notify. Maker shall notify Payee in writing (a) thirty (30) days in advance of a Significant Transaction,
and (b) provide Payee with any and all documents relating thereto within 48 hours of being requested by Payee, subject to Payee
executing with and in favor and to the satisfaction of Maker an agreement pursuant to which it agrees to restrictions on the disclosure,
use and ownership of any and all such documents and information contained therein. These rights set forth in this Section shall
terminate upon the repayment of the 2019 Note in full.

 

3.            
Option to Elect Payment in Conversion Shares. Notwithstanding any provision of this 2019 Note to the contrary,
Payee shall have the option, exercisable in his sole and absolute discretion at any time commencing with the Issue Date and ending
as of the date on which the Unpaid Balance of this 2019 Note is paid in full, to Convert all or any portion of the Unpaid Balance
as determined on the Conversion Date into Conversion Shares, in such number of Conversion Shares as shall equal that portion of
the Unpaid Balance as Payee may elect in his discretion to be converted, divided the Conversion Share Price.

 

4.            
Prepayment. This 2019 Note may be prepaid prior to the Maturity Date at the option of Maker in cash, without
premium or penalty, at the Principal amount so to be prepaid, together with interest accrued thereon to the date fixed for such
prepayment; provided, however, that in no event may any such prepayment or other cash payment be made until and unless Maker
shall have given prior written notice of its intent to pay all or any portion of this 2019 Note to Payee, which notice shall be
given not less than ten (10) nor more than thirty (30) days prior to the date fixed for such payment in such notice and shall specify
the amount so to be paid and the date fixed for such payment (the “Notice Period”). Notwithstanding any provision of
this 2019 Note to the contrary, during such Notice Period, Payee may exercise Payee’s rights under Section 3 of this 2019
Note to cause the Conversion all or any part of the Unpaid Balance to Conversion Shares. Subject to the foregoing, upon the giving
of notice of its payment, Maker shall pay on the date therein fixed for any such payment.

 

    -2-

     

    

 

5.             
 Payments Credited First Against Interest. Notwithstanding any provision in this 2019 Note to the contrary, any
payment of this 2019 Note, whether as a partial payment or in full, will be credited first against accrued interest, then Principal,
in reverse chronological order.

 

6.            
Surrender of2019 Note. Upon any such partial payment of the Unpaid Balance, this 2019 Note, at the election of
Maker, shall be either (a) surrendered to Maker in exchange for a new 2019 Note in a Principal amount equal to Unpaid Balance on
the 2019 Note surrendered, and otherwise having the same terms and provisions as this 2019 Note (and for purposes of the foregoing
provisions of this Section to be deemed to be the same 2019 Note and not a novation of the indebtedness represented thereby), or
(b) made available to Maker at the principal office of Maker for notation thereon of the portion thereof so prepaid. Upon payment
in full of the amount of the Unpaid Balance, this 2019 Note shall be surrendered to the Maker for cancellation.

 

7.             
Definitions. For purposes of this 2019 Note, the following terms and phrases shall have the meaning ascribed
thereto:

 

(a)              
“Common Stock” shall have the meaning ascribed thereto in Maker’s Articles of Incorporation, as the same
shall have been or is amended from time to time.

 

(b)              
“Conversion” or “Converted” shall mean the payment and satisfaction of the Unpaid Balance or such
portion thereof as provided in this 2019 Note by Maker’s issuance to Payee of Conversion Shares in accordance with the terms
hereof.

 

(c)              
“Conversion Date” shall mean any such date on which all or any portion of the Unpaid Balance shall be paid by
Maker at Payee’s election as provided in this 2019 Note by Maker’s issuance to Payee of Conversion Shares.

 

(d)              
“Conversion Exercise Date” shall mean the date on which the exercise by Payee of his right to cause the payment
of all or any portion of this 2019 Note in Conversion Shares is made effective; provided, however, that the exercise
by Payee of his Conversion right is delivered to Maker in writing.

 

(e)              
“Conversion Share(s)” shall mean that number of Shares of Common Stock to which Payee is entitled in payment,
whether in whole or in part, of the Unpaid Balance in accordance with the terms and conditions of this 2019 Note.

 

(f)               
“Conversion Share Price” shall mean that amount as shall equal the Fair Market Value of each Share of Maker’s
Common Stock (as determined on an as converted and fully diluted basis) as such per Share value and number of Shares of Common
Stock are determined to exist as of the Conversion Exercise Date.

 

(g)              
“Fair Market Value” means, as of the Conversion Exercise Date, the fair market value of a Share of Maker’s
Common Stock determined as follows:

 

(i)                 If
the Shares are readily tradable on a Securities Market, by the closing price of a Share on the Conversion Exercise Date as
reported on the composite tape for securities traded on the Securities Market. If a closing price was not reported on that
date, then the arithmetic mean of the high and low prices at the close of the market on that date, and if these prices were
not reported on that date, then the closing price on the last trading day on which a closing price was reported; or

 

    -3-

     

    

 

(ii)             
If Maker’s Board or Directors (the “Board”) in its reasonable discretion determines that the Shares are
not readily tradable on a Securities Market, by an independent written appraisal that satisfies the requirements of Internal Revenue
Code Section 401(a)(28)(C) as of the Conversion Exercise Date (the “Appraisal”).

 

(iii)           
Once the Conversion Share Price has been established, the Board shall not change the same through the retroactive use of
another valuation method.

 

(iv)            
Shares are treated as readily tradable on a Securities Market if they are regularly quoted by brokers or dealers making
a market in the Shares.

 

(h)              
“Government Body” means: (i) the government of any country, or the government of any political subdivision of
any country (a “Government”); (ii) any instrumentality of a Government; (iii) any other Person authorized by Law to
perform any administrative, executive, judicial, legislative, military, police, or regulatory functions of a Government; (iv) any
intergovernmental organization; and (v) any successor to the entities listed under Clauses (i) to (iv).

 

(i)                
“Initial Public Offering” means the first underwritten offering or listing of Shares of Maker or any successor
to Maker when such Shares are offered pursuant to an effective registration statement under the Exchange Act.

 

(j)                
“Law” means: (i) an administrative decision on which Persons other than those to whom the decision was issued
can rely; (ii) a judicial decision on which Persons other than those to whom the decision was issued can rely; (iii) an ordinance
or statute; (iv) a regulation or rule; or (v) any combination of the items under Clauses (i) to (iv).

 

(k)              
“Person” means a business trust, corporation, estate, general partnership, individual, limited liability company,
limited liability partnership, limited partnership, sole proprietor, trust, or other entity.

 

(l)                
“Securities Market” means: (i) a national securities exchange that is registered under Section 6 of the Securities
Exchange Act of 1934, as amended; (ii) a foreign national securities exchange that is officially recognized, sanctioned, or supervised
by a Government Body; or (iii) any over-the-counter market that uses an interdealer quotation system. An interdealer quotation
system is any system of general circulation to brokers and dealers that regularly disseminates quotations of stocks and securities
by identified brokers or dealers, other than by quotation sheets that are prepared and distributed by a broker or dealer in the
regular course of business and that contain only quotations of that broker or dealer.

 

(m)            
“Share” means a share of Common Stock.

 

    -4-

     

    

 

(n)              
“Significant Transaction” shall mean any one of the following:

 

(i)                
 Any transaction (or the first tranche of any series of integrated transactions) pursuant to which Maker sells, transfers,
leases, exchanges or disposes of all or substantially all of its assets for cash or property, or for a combination of cash and
property, or for other consideration; or

 

(ii)             
Any transaction, whether in a single or series of related steps, pursuant to which (1) any Person (or group of Persons)
acquires within a twelve (12) consecutive calendar month period by merger, consolidation, reorganization, division or other business
combination or transaction or by a purchase of an interest in Maker such that after any such transaction, the holders of ownership
interests of Maker immediately prior to such transaction no longer have a controlling interest in Maker (or any successor-in-interest
thereof); or (2) the shares of capital stock of Maker or any successor thereto are traded on a Securities Market, whether as a
result of an Initial Public Offering or via a reverse merger by Maker into a company the capital stock of which is traded on a
Securities Market;

 

(o)              
“Person” shall mean any individual, partnership, limited partnership, limited liability partnership, limited
liability company, corporation, trust, association, non-profit or charitable organization or other entity, or an unincorporated
organization, a governmental entity or any department or agency thereof.

 

(p)              
“Unpaid Balance” shall mean the amount of accrued and outstanding, but unpaid Principal and such amount of interest
as shall have accrued thereon as provided in Section 1 of this 2019 Note through and including any date fixed for payment, whether
in whole or in part, under this 2019 Note.

 

8.             
No Fractional Shares. Instead of any fractional Conversion Shares that would otherwise be issuable upon conversion
of this 2019 Note, Maker shall pay a cash adjustment in respect of such fractional interest in an amount equal to the product of
(a) the applicable Conversion Share Price and (b) such fractional interest. The holder of fractional interests shall not be entitled
to any rights as security holders of Maker in respect of such fractional interests.

 

9.             
No Impairment. Maker shall not, by amendment of its Articles of Incorporation or Bylaws, each as amended to date,
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this 2019 Note, but shall at all
times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate
in order to protect the rights of Payee against dilution or other impairment.

 

10.          
Events of Default. The occurrence or existence of any one of the following events or conditions shall constitute
an “Event of Default”:

 

(a)              
Maker shall fail to pay the Principal of, or interest on, this 2019 Note when the same becomes due and payable in accordance
with the terms hereof and such amount remains unpaid for ten (10) business days after the due date thereof;

 

(b)               Maker
fails to observe or perform any other covenant or agreement on the part of Maker contained in this 2019 Note which failure
continues for a period of thirty (30) days (except in the case of its obligation under Section 3 of this 2019 Note, in which
case the period shall be three (3) days) after the date of written notice thereof from Payee; or

 

    -5-

     

    

 

(c)              
Maker makes a general assignment for the benefit of its creditors or applies to any tribunal for the appointment of a trustee
or receiver of a substantial part of the assets of Maker, or commences any proceedings relating to Maker under any bankruptcy,
reorganization, arrangement, insolvency, readjustment of debts, dissolution or other liquidation law of any jurisdiction; or any
such application is filed, or any such proceedings are commenced against Maker and Maker indicates its consent to such proceedings,
or an order or decree is entered by a court of competent jurisdiction appointing such trustee or receiver, or adjudicating Maker
bankrupt or insolvent, or approving the petition in any such proceedings, and such order or decree remains unstayed and in effect
for ninety (90) days.

 

11.          
Remedies. If an Event of Default occurs and is continuing, Payee may, by notice in writing to Maker, declare
the entire Unpaid Balance of this 2019 Note to be due and payable immediately, and upon any such declaration, the entire Unpaid
Balance of this 2019 Note shall become and be immediately due and payable, and Payee may thereupon proceed to protect and enforce
its rights either by suit in equity or by action at law or by other appropriate proceedings, whether for specific performance (to
the extent permitted by law) of any covenant or agreement contained herein or in aid of the exercise of any power granted herein,
or proceed to enforce the payment of this 2019 Note or to enforce any other legal or equitable right of Payee. In the event this
2019 Note is placed in the hands of an attorney for collection or for enforcement, or in the event that Payee incurs any costs
incident to the collection of any indebtedness evidenced hereby, Maker agrees to pay all reasonable attorneys’ fees and expenses,
all court and other costs and the reasonable costs of any other collection efforts. Forbearance to exercise the remedies set forth
herein with respect to any failure or breach of Maker shall not constitute a waiver by Payee of any of such remedies.

 

12.            Expenses. Except as otherwise provided in this 2019 Note, each of Maker and Payee shall bear its own costs incurred
in connection with the negotiation, documentation and execution of this 2019 Note, the closing of the transactions contemplated
herein, and any amendment, waiver, consent, supplement or modification hereto.

 

13.           
Notices. All notices, requests, consents and other communications required or permitted under this 2019 Note
shall be in writing and shall be deemed to have been delivered three (3) days after the date mailed, postage prepaid, by certified
mail, return receipt requested, or on the date personally delivered:

 

	
        If to Maker, to:

         

        Inhibikase Therapeutics, Inc. Attn: Chief Executive Officer
        3350 Riverwood Parkway Suite 1900, Atlanta, Georgia 30339
	
        If to Payee, to:

         

        Flagship Consulting, Inc.

        Frattaroli

        131 Daniel Webster Hwy, #322 Nashua, NH 03060

 

If to any Payee other than Payee, to such
address as may have been designated by notice given Maker by such Payee. Maker, Payee or any other Payee may designate a different
address by notice given in accordance with the foregoing.

 

    -6-

     

    

  

14.           
Waiver and Amendment. Any provision of this 2019 Note may be amended, waived or modified upon the written consent
of Maker and Payee.

 

15.           
Assignment; Binding Effect. Payee shall neither be entitled to assign nor assign all or any portion of its performance
obligations under this 2019 Note and any attempted assignment hereof shall be void and of no effect. Subject to the preceding sentences,
this 2019 Note shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors,
administrators, successors and assigns.

 

16.            Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
GEORGIA WITHOUT GIVING EFFECT TO CONFLICTS OF LAWS PRINCIPLES.

 

17.            Venue.
EACH OF THE PARTIES HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE JURISDICTION OF THE
COURTS OF THE STATE OF GEORGIA SITTING IN COBB COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE DISTRICT OF GEORGIA, AND
ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR
RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT
ALLCLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH STATE OR, TO THE EXTENT PERMITTED
BY LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL
BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW.
MAKER AND HOLDER HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO,
ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR
RELATING TO THIS AGREEMENT IN ANY COURT REFERRED TO IN THIS SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO
THE FULLEST EXTENT PERMITTED BY LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN
ANY SUCH COURT. EACH PARTY TO THIS AGREEMENT IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN
SECTION 13 OF THIS 2019 Note. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY TO THIS AGREEMENT TO SERVE PROCESS
IN ANY OTHER MANNER PERMITTED BY LAW.

 

    -7-

     

    

 

	 	Inhibikase Therapeutics, Inc.
	 	 
	 	By:  	/s/ Milton Werner
	 	 	Milton Werner, Ph.D., Authorized Officer

 

	ACCEPTED
    AND AGREED TO:	 
	 	 
	/s/
    Joseph Frattaroli	 

	By:	Joseph
    Frattaroli	 
	Date:	12/31/2019	 

 

    -8-

     

    

 

Exhibit
A

 

Schedule

Of

Fees & Costs

 

	Date of Statement	Fees Accrued To 

Date	PaymentsExhibit 4.10

 

Execution Copy

 

RESTATED AGREEMENT
TO

REPAY INDIVIDUAL
LOAN

 

THE
AGREEMENT TO REPAY AN INDIVIDUAL LOAN (the “Agreement”) that was initially entered into on the 5th of
February, 2020 is RESTATED this 13th day of June, 2020 (the “Effective Date”), into by and between Inhibikase
Therapeutics, Inc., a Delaware corporation (“Corporation”) and Milton H. Werner, Ph.D., individually a resident of
the State of Georgia (“the Individual“).

 

1.             Corporation Loan.

 

		(a)	The Amount. The Individual will loan the Corporation a principal
amount of $248,911. The date of the funding of such loan is the Loan Issue Date.

 

		(b)	Terms of Repayment. The principal amount of Individual Loan is to
be repaid by Corporation, either in full or in part until paid in full, as the case may be, without demand and in immediately available
funds, in lump sum on the earlier to occur of either (i) the thirtieth (30th) month following the Loan Issue Date or
(ii) the date on which the Corporation has sufficient funds to repay the Individual Loan (together, the “Maturity Date”);

 

		(c)	Interest. From and including the Loan Issue Date to and including
the Maturity Date, the Individual Loan shall bear simple interest at current Federal Funds rate of 0.25%, compounded semi-annually.
Such interest shall be payable on the Maturity Date.

 

		(d)	Tender. All payments of principal and interest shall be made in lawful
money of the United States of America and shall be made by Corporation via wire transfer to an account designated by the Individual
or, if no account is so designated, at the Individual’s address set forth in Section 5 or at such other place as the Individual
may designate in writing.

 

		(e)	Right of Prepayment; Allocation. Corporation shall have the right
to repay the Individual Loan at any time during the term hereof without penalty. Any payments received by the Individual hereunder
shall be applied as follows: first, to any costs and expenses due to Individual hereunder; second, to accrued but unpaid interest
hereon; and third, to pay the unpaid principal balance hereunder.

 

2.             Events of Default. The occurrence or existence of any one of the following events or conditions shall constitute
an “Event of Default”:

 

(a)         Corporation shall fail to pay the principal of, or interest on, Individual Loan when the same becomes due and payable in
accordance with the terms hereof and such amount remains unpaid for ten (10) business days after the due date thereof; or

 

(b)         Corporation
makes a general assignment for the benefit of its creditors or applies to any tribunal for the appointment of a trustee or
receiver of a substantial part of the assets of Corporation, or commences any proceedings relating to Corporation under any
bankruptcy, reorganization, arrangement, insolvency, readjustment of debts, dissolution or other liquidation law of any
jurisdiction; or any such application is filed, or any such proceedings are commenced against Corporation and Corporation
indicates its consent to such proceedings, or an order or decree is entered by a court of competent jurisdiction appointing
such trustee or receiver, or adjudicating Corporation bankrupt or insolvent, or approving the petition in any such
proceedings, and such order or decree remains in effect for ninety (90) days.

 

    	Restated Corporation Loan to Werner
	1 

    

    

 

Execution Copy

 

3.            Remedies. If an Event of Default occurs and is continuing, Individual may, by notice in writing to Corporation,
declare the entire unpaid principal of Individual Loan to be due and payable immediately. The Corporation agrees to issue a Warrant
to purchase the number of shares equal to 150% the value of the loan at an individual share price of $4.81 in the case of any default.
In the Event of a Default, the Warrant will remain in effect even after the loan is repaid.

 

4.            Expenses. Except as otherwise provided in this Individual Loan, Employee and Corporation shall bear its own costs
incurred in connection with the negotiation, documentation and execution of this Individual Loan, the closing of the transactions
contemplated herein, and any amendment, waiver, consent, supplement or modification hereto.

 

5.            Notices. All notices, requests, consents and other communications required or permitted under this Indivual Loan
shall be in writing and shall be deemed to have been delivered three (3) days after the date mailed, postage prepaid, by certified
mail, return receipt requested, or on the date personally delivered:

 

	If to Corporation, to:	If to Individual, to: 
	 	 
	Inhibikase
Therapeutics, LLC 

Attn: Chief Executive

3350 Riverwood Parkway, Suite 1900

Atlanta, GA 30339	Milton H. Werner, PhD

874 Birds ML SE

Marietta, GA 30067  

 

Individual and Corporation may designate a different address by notice given in accordance with the foregoing.

 

6.            Individual’s Representations and Warranties. Individual hereby represents and warrants to Corporation that
the statements contained in this Section are true, correct and complete as of the date of this Individual Loan: (a) Individual
is a resident of the State of Georgia; (b) Individual has full power and authority (including full corporate power and authority)
to execute and deliver this Individual Loan and to perform its obligations hereunder; (c) this Individual Loan constitutes the
valid and legally binding obligation of Corporation, enforceable in accordance with its terms and conditions; (d) the execution,
delivery and performance of this Individual Loan and all other agreements contemplated hereby have been duly authorized by Corporation;
(e) neither the execution and delivery of this Individual Loan, nor the consummation of the transactions contemplated hereby, will
(i) violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction
of any government, governmental agency, or court to which Individual is subject or any provision of its charter, bylaws, or other
governing documents, (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create
in any party the right to accelerate, terminate, modify, or cancel, or require any notice under any agreement, contract, lease,
license, instrument, or other arrangement to which Individual is a party or by which it is bound or to which any of its assets
is subject, (iii) result in the imposition or creation of a lien upon or with respect to its assets or (iv) require the prior written
consent of any third party.

 

7.            Waiver and Agreement. Any provision of this Individual Loan may be amended, waived or modified upon the written
consent of Individual and Corporation.

 

8.            Assignment;
Binding Effect. Corporation shall not be entitled to assign all or any portion of its performance obligations under
this Individual Loan and any attempted assignment hereof shall be void and of no effect. Individual may assign this
Individual Loan and its right to receive payment hereunder. Subject to the preceding sentences, this Individual Loan shall be
binding upon and shall inure to the benefit of the parties hereto and their respective heirs, executors, administrators,
successors and assigns.

 

    	Restated Corporation Loan to Werner
	2 

    

    

 

Execution Copy

 

9.            Governing Law and Waiver of Jury Trial. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF THE STATE OF GEORGIA WITHOUT GIVING EFFECT TO CONFLICTS OF LAWS PRINCIPLES. THE PARTIES HERETO WAIVE ALL RIGHTS TO
TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE, WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE
BETWEEN THE PARTIES ARISING OUT OF, CONNECTED WITH, RELATED TO, OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION
WITH THIS AGREEMENT OR MATTERS RELATED HERETO.

 

10.          Venue. MAKER
HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE JURISDICTION OF THE COURTS OF THE STATE
OF GEORGIA SITTING IN COBB COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE DISTRICT OF GEORGIA, AND ANY APPELLATE COURT
FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT
OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF
ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH STATE OR, TO THE EXTENT PERMITTED BY LAW, IN SUCH FEDERAL
COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY
BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT
SHALL AFFECT ANY RIGHT THAT HOLDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AGAINST
MAKER OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. MAKER AND HOLDER HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO
THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF
VENUE OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY COURT REFERRED TO IN THIS
SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, THE DEFENSE OF AN
INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT. EACH PARTY TO THIS AGREEMENT
IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 5 OF THIS NOTE. NOTHING IN THIS
AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY TO THIS AGREEMENT TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

 

    	Restated Corporation Loan to Werner
	3 

    

    

 

Execution Copy

 

	 	Milton H Werner, PhD,
    an Individual
	 	 
	 	 
	 	By:	      

  

	ACCEPTED AND AGREED TO:	 
	 	 
	Inhibikase Therapeutics,
    Inc.	 
	 	 
	Elizabeth O’Farrell	 
	Authorized Board Member	 

 

    	Restated Corporation Loan to Werner
	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]